Pradaxa antidote data lets Boehringer 'keep up' in oral anticoagulant race
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has presented the first clinical data for its antidote to Pradaxa (dabigatran), which could boost sales of the new anticoagulant treatment for patients with atrial fibrillation. With competitors Eliquis and Xarelto being tested in Phase II with Portola Pharmaceuticals' 'universal antidote', the positive data will come as a relief to Boehringer.